Arcturus Therapeutics Holdings

ARCT

Biotech & pharmaceuticals

$12.95vs prev close▼-0.50(-3.72%)

$5.5052W Range$24.17

40% from low

+8.81 (+159.31%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

No trades in 1M

1M net buy

≈ 0 shares

Portfolio Weight

0.14%

1M -0.01%p

Holding ETFs

1 ETFs

ARKG

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -0.6% · Market value -15.4% · Weight -0.01%p

Trade Intensity

No trades in 1M

Trade Log

Date	Action	ETF	Shares	Close	Est. total
26.04.09	BUY	ARKG	3,447	$8.22	$28.3K
26.04.08	BUY	ARKG	4,787	$8.50	$40.7K
26.04.02	BUY	ARKG	636	$8.03	$5.1K
26.04.01	BUY	ARKG	7,182	$7.85	$56.4K
26.03.30	BUY	ARKG	8,855	$6.90	$61.1K
26.03.27	BUY	ARKG	48,659	$6.76	$328.9K
26.03.24	BUY	ARKG	4,525	$6.65	$30.1K
26.03.20	BUY	ARKG	22,773	$6.63	$151.0K
26.03.19	BUY	ARKG	6,905	$6.72	$46.4K
26.03.18	BUY	ARKG	33,864	$6.55	$221.8K
26.03.03	BUY	ARKG	74,816	$7.91	$591.8K
25.12.09	BUY	ARKG	17,732	$7.20	$127.7K
25.12.08	BUY	ARKG	44,974	$7.45	$335.1K
25.12.05	BUY	ARKG	116,003	$7.13	$827.1K
25.10.24	BUY	ARKG	10,818	$11.22	$121.4K

04.09BUY

3,447

ARKGClose$8.22Est. total$28.3K

04.08BUY

4,787

ARKGClose$8.50Est. total$40.7K

04.02BUY

636

ARKGClose$8.03Est. total$5.1K

04.01BUY

7,182

ARKGClose$7.85Est. total$56.4K

03.30BUY

8,855

ARKGClose$6.90Est. total$61.1K

03.27BUY

48,659

ARKGClose$6.76Est. total$328.9K

03.24BUY

4,525

ARKGClose$6.65Est. total$30.1K

03.20BUY

22,773

ARKGClose$6.63Est. total$151.0K

03.19BUY

6,905

ARKGClose$6.72Est. total$46.4K

03.18BUY

33,864

ARKGClose$6.55Est. total$221.8K

03.03BUY

74,816

ARKGClose$7.91Est. total$591.8K

12.09BUY

17,732

ARKGClose$7.20Est. total$127.7K

12.08BUY

44,974

ARKGClose$7.45Est. total$335.1K

12.05BUY

116,003

ARKGClose$7.13Est. total$827.1K

10.24BUY

10,818

ARKGClose$11.22Est. total$121.4K

1 / 4

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

2,734,331

Portfolio Weight

0.14%

in ETF 1.03%

Est. Value

$17M

30D Net

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Analyst Targets

avg.

$20.20

vs Current ▲ +50.2% upside

Current$13.45

Low ~ High$8.00 ~ $40.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Freedom Broker

Buy

$27.00

+100.74%

$7.28

Upgrade

2026-07-02

B. Riley Securities

Buy

$22.00

+63.57%

$6.55

Upgrade

2026-03-18

Citigroup

Buy

$21.00

+56.13%

$7.25

Maintain

2026-03-05

Citigroup

Neutral

$8.00

-40.52%

$7.58

Maintain

2026-03-04

Piper Sandler

Overweight

$25.00

+85.87%

$7.58

Maintain

2026-03-04

1 / 4

Avg Target

$20.20

vs Current ▲ +50.2% upside

Buy

13 analysts

Strong Buy 1Buy 9Hold 3

Low $8.00

Current $13.45

High $40.00

Firm	Position	Target	Upside	Close	Action	Date
Freedom Broker	Buy	$27.00	+100.74%	$7.28	Upgrade	26.07.02
B. Riley Securities	Buy	$22.00	+63.57%	$6.55	Upgrade	26.03.18
Citigroup	Buy	$21.00	+56.13%	$7.25	Maintain	26.03.05
Citigroup	Neutral	$8.00	-40.52%	$7.58	Maintain	26.03.04
Piper Sandler	Overweight	$25.00	+85.87%	$7.58	Maintain	26.03.04

1 / 4

Price Information

Previous Close$13.45

Open$11.13

Day Range$11.11 - $13.50

52-Week Range$5.50 - $24.17

1-Year Change-24.05%

Trading Volume

Volume2,848,253

Avg Volume (3mo)650,991

Valuation

Market Cap382.3M

Book Value$6.04

Shares Outstanding28,423,069

Financials

Revenue (TTM)29.4M

Net Income-93,276,000

EPS$-3.33

EBITDA-99,548,000

Profitability

P/E Ratio-

P/B Ratio2.22

Return on Equity (ROE)-46.31%

Return on Assets (ROA)-23.96%

Profit Margin0.00%

EV/EBITDA-2.15

Beta2.27

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)92.77

Company Overview

Arcturus Therapeutics Holdings is a biotechnology company focused on developing vaccines for infectious diseases and therapeutics for rare liver and respiratory diseases. They utilize LUNAR lipid-mediated delivery and STARR mRNA technology platforms to advance candidates like ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032 for cystic fibrosis. The company is also developing COVID-19 vaccines and influenza vaccines, with several candidates in various stages of clinical trials.

P/B

2.22

Price-to-Book

ROE

-46.3%

Persistent loss

Beta

2.27

Extreme volatility

RSI(14)

92.8

Overbought

AI-generated summary. Not investment advice.

Arcturus Therapeutics Holdings

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks